Minimally Invasive Non-surgical Therapy With or Without Injectable Bone Putty

NCT ID: NCT06553222

Last Updated: 2024-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-04

Study Completion Date

2025-12-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

• All periodontitis patients with infra bony pockets to be included in this study will diagnosed as having stage III periodontitis with probing pocket depth (PPD) ≥ 6 mm, and clinical attachment loss (CAL) ≥ 5mm will be treated by minimally invasive non-surgical therapy or by injectable bone putty

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The present study will be designed as a randomized controlled clinical and radiographic. The study will be carried out on stage III grade (B) periodontitis patients with intra-bony defects. Those patients will be selected from the outpatient clinics of the Department of Oral Medicine and Periodontology, Faculty of Dental Medicine, Al-Azhar University, Assiut branch.

The study has bee approved by the ethical committee, Faculty of Dental medicine, Al-Azhar University, Assiut branch.

2\. All patients will be fully informed about the study's nature and the possible risks of the study procedures; they sign the consent form before the work.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Bone Defects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

2 parallel groups study group - The interventional group where minimally invasive debridement flap and a putty bone graft is tested and the Control group - where minimally invasive debridement flap is performed without graft
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
the outcome assessor will assess the bone gain (Radiographic) and Clinical attachment level (clinical) in both groups. the assessor is blinded whether a graft was loaded at the time of surgery

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interventional

Participants receives Injectable bone putty - Minimally invasive debridement periodontal flap plus putty bone graft in three osseous wall defect

Group Type EXPERIMENTAL

Putty bone - Tricalcium phosphate with Collagen gel

Intervention Type BIOLOGICAL

Minimally invasive debridement periodontal flap and Bone graft placement to augment the lost alveolar bone

Control group

\- Participants receive No graft (No drug) Minimally invasive debridement periodontal flap

Group Type PLACEBO_COMPARATOR

Putty bone - Tricalcium phosphate with Collagen gel

Intervention Type BIOLOGICAL

Minimally invasive debridement periodontal flap and Bone graft placement to augment the lost alveolar bone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Putty bone - Tricalcium phosphate with Collagen gel

Minimally invasive debridement periodontal flap and Bone graft placement to augment the lost alveolar bone

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • All periodontitis patients to be included in this study should be diagnosed as having stage III periodontitis with probing pocket depth (PPD) ≥ 6 mm, and clinical attachment loss (CAL) ≥ 5mm.

* 2- or 3-wall intra-bony interproximal defect with depth ≥3 mm, a width of ≥3 mm at its most coronal part and 45-55-degree angulation will be selected in order to reduce defect variability
* All patients will be free from any systemic diseases according to the American Dental Academy general guidelines for referring dental patients to specialists and other care settings.

Exclusion Criteria

• Any patients with any systemic condition that contraindicate any surgical intervention
Minimum Eligible Age

35 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Al-Azhar University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hagar Ahmed Saad

Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AUAREC20240007-5

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.